VRCA: Verrica Company Aggregate Debts

Symbol and logo of brand verrica.com (VRCA)

The development of Verrica Pharmaceuticals (VRCA) relies on stable, recession-proof demand within the biotech sector. The rise in share prices confirms the expansion of YCANTH into US clinics, while exclusive patents ensure a monopoly in dermatology. Regarding the total debt structure, this chart from GURU.Markets shows that the 0.00 mark reflects the latest data on borrowed capital affecting the company's bottom line.

VRCA: Verrica Pharmaceuticals Inc Company Debts 07/04/2022 - 11/01/2026

Verrica Pharmaceuticals (VRCA) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart verrica.com|VRCA - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Verrica|VRCA - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Verrica Pharmaceuticals|VRCA - Company Book Value|Market Cap to Net Assets Ratio verrica.com|VRCA - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Verrica Pharmaceuticals|VRCA - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital verrica.com|VRCA - Company Debts|Debts to Net Assets Verrica|VRCA - Company Long-Term Debt|Company Short-Term Debts Verrica Pharmaceuticals|Interim Coverage Ratio verrica.com
- earnings and valuation multiples information:
VRCA - Company Net Income
Fundamental company analysis:VRCA, Verrica Pharmaceuticals Inc
Signature product of Verrica Pharmaceuticals Inc.

Investors assess balance sheet resilience by analyzing the debt-to-equity ratio, where the total debt trajectory reflects the business's reliance on external financing and the cost of future refinancings. For Verrica Pharmaceuticals (VRCA), this indicator demonstrates the financial leverage utilized to develop dermatological products while maintaining minimal expenditures on the environmental modernization of plastic applicators and the digitalization of document workflows.

Competitors of Verrica Pharmaceuticals

KRYS (Krystal Biotech Corp.) - Aggregate Debt Obligations|Company Aggregate Debts APGE (Apogee Therapeutics)|Company Aggregate Debts arcutis.com ARQT|VCEL - Company Debts|Aggregate Debt Obligations ORKA (Oruka Therapeutics, Inc.)|sanaramedtech.com (SMTI) - Company Debts|Company Total Debt DBV Technologies|SLSN (Solesence Beauty) - Company Aggregate Debts|Company Aggregate Debts Journey Medical Corp.|Company Total Debt FBRX (Forte Biosciences)|EMPG (Empro Group Inc.) - Aggregate Debt Obligations|Company Debts Sol-Gel SLGL|Company Total Debt Obligations AXIL Brands Inc (AXIL)|MDCX - Company Debts|HOTH - Company Aggregate Debts|BFRI: Company Aggregate Debts|VYNE - Company Total Debt Obligations|Company Debts Sonoma Pharmaceuticals Inc.|Company Aggregate Debt QNRX (Quoin Pharma)|Company Total Debt AZTR (Azitra, Inc.)|Company Debts DRMA (dermatarx.com)|Company Aggregate Debts ELAB (Elevai Labs)|Revance Therapeutics Inc. (RVNC) - Company Cumulative Debt